You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Novel Once-Weekly Basal Insulins: Expert Interpretation of Latest Clinical Data

  • Authors: Harpreet S. Bajaj, MD, MPH; Athena Philis-Tsimikas, MD
  • CME Released: 10/18/2022
  • Valid for credit through: 10/18/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK diabetologists/endocrinologists, primary care physicians, and other physicians/healthcare professionals/nurses involved in the care of persons with T2D.

The goal of this activity is for learners to be better able to improve their understanding of the continued role of basal insulin in the management of T2D, address barriers to its initiation, and increase the awareness of novel once-weekly basal insulin formulations.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Basal insulin therapy in the management of T2D
    • Clinical profile of emerging once-weekly basal insulin formulations
  • Have greater competence related to
    • The identification of patients with T2D as suitable candidates for future treatment with once-weekly basal insulins


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Harpreet S. Bajaj, MD, MPH

    Consultant Endocrinologist and Medical Director
    Endocrine and Metabolic Research
    LMC Healthcare
    Research Associate
    Leadership Sinai Centre for Diabetes
    Mount Sinai Hospital
    Toronto, Ontario, Canada

    Disclosures

    Harpreet S. Bajaj, MD, MPH, has the following relevant financial relationships:
    Research funding from: Amgen; AstraZeneca; Boehringer Ingelheim; Ceapro; Eli Lilly; Gilead Sciences; Janssen; Kowa; Madrigal; Merck; Novartis; Novo Nordisk; Pfizer; Sanofi; Tricida

Faculty

  • Athena Philis-Tsimikas, MD

    Corporate Vice President
    Scripps Whittier Diabetes Institute at Scripps Health
    San Diego, California, United States

    Disclosures

    Athena Philis-Tsimikas, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bayer; Dexcom; Lilly; Minimed; Novo Nordisk
    Research funding from: Dexcom; Lilly; Minimed; Novo Nordisk

Editor

  • Rita Moreira Da Silva, PhD, MA, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Rita Moreira Da Silva, PhD, MA, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Novel Once-Weekly Basal Insulins: Expert Interpretation of Latest Clinical Data

Authors: Harpreet S. Bajaj, MD, MPH; Athena Philis-Tsimikas, MDFaculty and Disclosures

CME Released: 10/18/2022

Valid for credit through: 10/18/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to improve their understanding of the continued role of basal insulin in the management of T2D, address barriers to its initiation, and increase the awareness of novel once-weekly basal insulin formulations.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print